Topics:

News

News

rheumatoid arthritis

One very targeted clue to treatment failure: An observational study from Israel identifies Sephardic Jews as more likely than Ashkenazim to form antibodies against the biologic drug infliximab.

The biologic adalimumab improves pain and physical function in a randomized trial of patients with peripheral spondyloarthritis unable to take non-steroidal anti-inflammatory drugs.

A meta-analysis involving more than 40,000 patients finds that biologics have a 30% increased infection risk compared to DMARDs, which is greatest for patients who have also used methotrexate.

A new app-based registry focusing on rheumatoid and psoriatic arthritis and ankylosing spondylitis aims to use patient-generated data to resolve important unanswered clinical questions. Its rheumatologist sponsor urges you to encourage patients to join up.

A systematic review finds the technique highly sensitive and specific in diagnosing giant cell arteritis, especially useful when biopsy results are equivocal.

(OARSI2015) First results are now in for a large collaborative project whose goal is to rationalize OA research by finding the best imaging and biochemical measures of progression.

(OARSI2015) Musculoskeletal signs predict which patients will do poorly after joint replacement surgery, but the Medicare agency does not include these in rating hospitals. The information could also be useful for surgeons and patients, says this investigator.

Pages

Subscribe to News on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.